|Videos|June 30, 2022

Dr. Tian Zhang discusses tivozanib for advanced kidney cancer

Tivozanib (Fotivda) is approved by the FDA for the treatment of adult patients with relapsed or refractory advanced renal cell carcinoma who have received 2 or more prior systemic therapies.

Tian Zhang, MD, associate professor at UT Southwestern Medical Center, discusses the FDA-approved therapy tivozanib (Fotivda) for patients with relapsed or refractory advanced renal cell carcinoma, including ongoing trials further exploring the agent.

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.


Latest CME